<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Interneuron Vulnerability in Huntington's Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Striatal Interneuron Vulnerability in Huntington's Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
The striatum contains a diverse array of interneuron populations that modulate the activity of medium spiny projection neurons (MSNs) and regulate basal ganglia circuitry. In [Huntington's disease (HD)](https://pubmed.ncbi.nlm.nih.gov/3179951/), caused by an expanded CAG repeat in the [HTT gene](https://pubmed.ncbi.nlm.nih.gov/7649584/), these interneuron populations exhibit differential vulnerability that contributes significantly to circuit dysfunction and the characteristic motor and cognitive symptoms of the disease. Understanding striatal interneuron pathology provides critical insights into disease mechanisms and identifies potential therapeutic targets for intervention.
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Interneuron Vulnerability in Huntington's Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Striatal Interneuron Vulnerability in Huntington's Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
The striatum contains a diverse array of interneuron populations that modulate the activity of medium spiny projection neurons (MSNs) and regulate basal ganglia circuitry. In [Huntington's disease (HD)](https://pubmed.ncbi.nlm.nih.gov/3179951/), caused by an expanded CAG repeat in the [HTT gene](https://pubmed.ncbi.nlm.nih.gov/7649584/), these interneuron populations exhibit differential vulnerability that contributes significantly to circuit dysfunction and the characteristic motor and cognitive symptoms of the disease. Understanding striatal interneuron pathology provides critical insights into disease mechanisms and identifies potential therapeutic targets for intervention.
Striatal interneurons are inhibitory GABAergic neurons that provide local modulation of MSN activity, shaping the flow of information through the basal ganglia. Unlike the massive MSN degeneration that defines HD neuropathology, interneuron populations show selective and heterogeneous patterns of vulnerability. This differential susceptibility reflects cell-type-specific molecular programs, synaptic inputs, and intrinsic physiological properties that determine resilience or vulnerability to mutant huntingtin (mHTT) toxicity.
Parvalbumin-expressing interneurons represent the largest fast-spiking interneuron population in the striatum. These neurons provide powerful perisomatic inhibition onto MSNs, controlling MSN firing patterns and synchronizing striatal output. PV interneurons receive dense excitatory inputs from the cortex and thalamus, positioning them as critical regulators of corticostriatal integration. In HD, PV interneurons show significant degeneration, contributing to disinhibition of MSNs and network hypersynchrony that manifests as choreiform movements.
Striatal cholinergic interneurons, also known as tonically active neurons (TANs), are large aspiny neurons that release acetylcholine and modulate MSN excitability through muscarinic and nicotinic receptors. These neurons play essential roles in reward learning, attention, and movement regulation. Cholinergic interneurons exhibit progressive degeneration in HD, with loss of these cells contributing to the characteristic cognitive deficits and movement abnormalities seen in the disease.
Somatostatin-expressing interneurons represent another important striatal interneuron population, characterized by their late-spiking firing pattern and dendritic targeting. These neurons co-express neuropeptide Y (NPY) and nitric oxide synthase (NOS), enabling volume transmission of neuromodulatory signals. SST/NPY interneurons provide dendritic inhibition onto MSNs and regulate synaptic plasticity. These interneurons also show reduced numbers in HD, contributing to altered synaptic integration and circuit dysfunction.
Striatal calretinin-expressing interneurons represent a more resilient population compared to PV and cholinergic interneurons. These neurons receive less mHTT-induced toxicity and may be relatively spared in HD. The differential vulnerability among GABAergic interneuron subtypes reflects distinct molecular signatures and physiological properties that influence susceptibility to mutant huntingtin.
The most severely affected interneuron populations in HD include:
PV Interneurons: Significant loss occurs early in disease progression, with studies in human HD postmortem brain and mouse models demonstrating dramatic reductions in PV-positive neurons. This loss contributes to disinhibition of MSN activity and network hypersynchrony [@pmid24014043].
Cholinergic Interneurons: Progressive degeneration of cholinergic interneurons contributes to cognitive deficits, as these neurons are essential for attention and reward learning. The loss of cholinergic modulation disrupts striatal plasticity and adaptive behavior.
SST/NPY Neurons: Reduced numbers of somatostatin-expressing interneurons have been documented in HD models and human tissue, contributing to altered dendritic integration and impaired synaptic plasticity.
Calretinin Interneurons: This interneuron subtype demonstrates greater resilience to mHTT toxicity compared to other populations, potentially due to different molecular programs or reduced vulnerability to the specific cellular perturbations induced by mutant huntingtin.
Several cell-intrinsic mechanisms contribute to interneuron vulnerability in HD:
Mutant Huntingtin Aggregation: Mutant huntingtin forms intracellular aggregates that sequester essential cellular proteins, including transcription factors such as [CREB-binding protein](https://pubmed.ncbi.nlm.nih.gov/10436043/) (CBP), disrupting gene expression programs critical for neuronal survival and function [@pmid10436043].
Transcriptional Dysregulation: Abnormal interactions between mHTT and transcription factors including REST lead to widespread transcriptional alterations affecting genes involved in neuronal function, synaptic plasticity, and cell survival.
Mitochondrial Dysfunction: Interneurons in HD show impaired mitochondrial function, with reduced complex I, II, and IV activities leading to ATP depletion and increased reactive oxygen species generation [@pmid26561400]. The downregulation of [PGC-1α](https://pubmed.ncbi.nlm.nih.gov/17635942/) compromises mitochondrial biogenesis and antioxidant defense [@pmid23448445].
Altered Calcium Handling: Many striatal interneurons exhibit abnormal calcium dynamics that compound excitotoxicity vulnerability. Calcium dysregulation activates downstream death pathways including calpain-mediated proteolysis and mitochondrial permeabilization.
Impaired Autophagy: Defects in protein clearance mechanisms, including autophagy, allow toxic protein species to accumulate and impair cellular function.
The loss of interneuron populations produces profound circuit-level dysfunction:
Loss of Inhibition on MSNs: Reduced GABAergic inhibition from PV and other interneurons leads to MSN disinhibition and abnormal firing patterns.
Disrupted Corticostriatal Integration: Interneurons process and modulate cortical inputs to MSNs; their loss disrupts this critical integration.
Altered Thalamic Input: Thalamic afferents to interneurons are affected, compounding circuit dysfunction.
Network Hypersynchrony: Loss of inhibitory control produces pathological synchronization of neuronal activity, manifesting as the characteristic involuntary movements (chorea) in HD.
Several molecular pathways mediate interneuron vulnerability:
CREB Dysfunction: Altered CREB signaling disrupts expression of genes essential for neuronal survival and plasticity.
BDNF Signaling: Reduced [brain-derived neurotrophic factor](https://pubmed.ncbi.nlm.nih.gov/8626557/) (BDNF) trophic support compromises interneuron survival.
Oxidative Stress: Increased reactive oxygen species (ROS) production from mitochondrial dysfunction damages cellular components.
Neuroinflammation: Glial contributions to neuroinflammation compound neuronal vulnerability.
Interneuron loss contributes directly to the motor manifestations of Huntington's disease:
Chorea: Involuntary, dance-like movements result from disinhibition of MSN activity and disrupted basal ganglia output.
Dystonia: Abnormal postures develop from imbalances between direct and indirect pathway activity.
Bradykinesia: Slowed movement emerges as disease progresses and MSN degeneration advances.
Impaired Gait and Balance: Integration of motor programs is disrupted, leading to falls and coordination deficits.
Interneuron dysfunction produces significant cognitive impairment:
Executive Dysfunction: Planning, cognitive flexibility, and working memory depend on intact striatal circuitry.
Information Processing: Altered processing speed and attention result from disrupted corticostriatal integration.
Behavioral Changes: Personality alterations and psychiatric symptoms reflect limbic system involvement.
Several approaches target interneuron populations:
GABAergic Agonists: Enhancing inhibition can compensate for reduced interneuron-mediated GABA release.
Cholinergic Modulation: Restoring cholinergic signaling may improve cognitive function.
PV Interneuron Restoration: Cell-based therapies offer potential for replacing lost interneurons.
HTT Lowering: Reducing mutant huntingtin expression in interneurons may protect vulnerable populations.
Neurotrophic Factors: Supporting interneuron survival through BDNF or related factors.
Deep brain stimulation (DBS) targeting striatal output nuclei can modulate circuit dysfunction resulting from interneuron loss. Optogenetic approaches offer potential for precise control of interneuron activity.
Interneuron-specific biomarkers may enable tracking of disease progression. PET ligands targeting PV or cholinergic markers could reveal interneuron loss in premanifest individuals.
Understanding the molecular mechanisms underlying interneuron vulnerability continues to inform therapeutic development. Cell replacement approaches using stem cell-derived interneurons show promise for restoring circuit function.